#exelixis
Latest news and interesting information about exelixis.
Cabometyx Cuts Neuroendocrine Tumor Risk
Exelixis announces Cabometyx reduces neuroendocrine tumor progression risk by 74% in CABINET trial. New data presented at ASCO.
Exelixis CFO Senner Sells $1.75M in Stock
Exelixis CFO Christopher Senner sold $1.75 million worth of company stock. The company shows strong financial health.
Exelixis SVP Brenda Hefti sells $332,641 in stock
Exelixis SVP Brenda Hefti sells $332,641 in stock. Shares trade near 52-week high. Company valued at $12.25B. Details on Bond.az.
...